Cardurion is a clinical-stage cardiovascular biotechnology company developing new therapeutics for the treatment of heart failure and cardiovascular diseases. Cardurion's product pipeline includes our lead clinical asset, CRD-733, a PDE-9 inhibitor with the potential to improve cardiac function in heart failure patients. Cardurion has an exclusive licensing agreement with Astellas for the development and commercialization of CRD-733. Additionally, Cardurion has a strong cardiovascular development partnership with Takeda which is fueling drug discovery and preclinical development work being conducted in our internal research laboratories.